Earnings reversal puts Stepan’s latest quarter in focus
Stepan (SCL) is back on investors’ radar after first quarter 2026 results showed sales of US$604.51 million alongside a net loss of US$41.41 million, compared with net income a year earlier.
See our latest analysis for Stepan.
The shares have softened around the earnings release, with a 1-day share price return of a 1.55% decline and a 7-day share price return of a 3.55% decline. The 1-year total shareholder return of a 2.19% decline and 5-year total shareholder return of a 59.01% decline show pressure on longer term holders, despite a 7.70% year-to-date share price gain.
If this kind of mixed performance has you thinking about diversification, it could be worth scanning for other opportunities using a focused list of 17 top founder-led companies
With Stepan trading at US$50.79 alongside an intrinsic value estimate and an analyst price target that both sit higher, the key question is simple: is the stock on sale after a tough quarter, or is the market already pricing in future growth?
Most Popular Narrative: 32.3% Undervalued
Against the last close of $50.79, the most followed narrative pegs Stepan’s fair value at $75, framing the current price as a sizeable discount.
The startup of the new Pasadena, Texas site is expected to reach full contribution in the second half of 2025, which could boost volume growth and supply chain savings. This is likely to impact revenue and margins positively.
Analysts are building this $75 view on a mix of steady revenue expansion, firmer margins, and a future earnings multiple below the wider chemicals peer group. Curious how those moving parts fit together into one valuation story?
Result: Fair Value of $75 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this narrative can unravel if weak cash generation persists or if higher raw material costs and softer selling prices squeeze margins more than analysts expect.
Find out about the key risks to this Stepan narrative.
Next Steps
Given the mix of concern and optimism in this story, it makes sense to move quickly, review the underlying data yourself, and then weigh up 3 key rewards and 2 important warning signs
Looking for more investment ideas?
If you stop with just one stock, you risk missing out on other compelling setups, so take a few minutes to scan wider and pressure test your watchlist.
- Target dependable income by checking out companies screened as potential 12 dividend fortresses that may appeal if you prioritise yield and stability.
- Hunt for quality at a discount by reviewing the 48 high quality undervalued stocks that match your standards on fundamentals and pricing.
- Protect your downside by focusing on 70 resilient stocks with low risk scores that score well on resilience and balance sheet strength.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com